JOT107

What is MELAS Syndrome?

• Largest prevalence and patient population of the three indications currently being pursued
• Pursuit of MELAS Syndrome is based on several pre-clinical studies demonstrating resveratrol significantly increasing mitochondrial activity, which is the key issue to treating the disease
• JOTROL™​ is expected to be effective in other mitochondrial diseases, creating a significant platform product

MELAS, mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke, Syndrome is a progressive neurodegenerative disorder. Signs and symptoms can begin at any age however, they most often appear in childhood following a period of normal development. Symptoms include seizures, loss of appetite, weakness and pain as well as recurrent headaches. MELAS Syndrome results in stroke and dementia. It is prevalent in approx. 1 out of every 8,000 people in the U.S.A. No current treatment is available for MELAS Syndrome